8-K Announcements
6Material company update
May 27, 2026·SEC
Material company update
May 26, 2026·SEC
Material company update
May 15, 2026·SEC
Traws Pharma, Inc.(TRAW)Earnings, Financials & Key Ratios
TRAW•NASDAQ
$0.83
1.0× P/E·Price updated Jun 27, 2026
AboutTraws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Show more
- Revenue$3M+1134.5%
- EBITDA-$18M+63.9%
- Net Income$9M+116.8%
- EPS (Diluted)0.82+102.3%
- Gross Margin100%+5.6%
- EBITDA Margin-638.49%+97.1%
- Operating Margin-640.68%+97.1%
- Net Margin328.67%+101.4%
TRAW Price & Volume
Traws Pharma, Inc. (TRAW) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Corporate Solvency Outlook
Investment Thesis • Updated 2026Q2
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
"Traws Pharma faces a precarious outlook as its commercial revenue has effectively evaporated to zero in 2026Q2, leaving the firm entirely dependent on external financing to sustain its R&D pipeline. The company's financial position is severely compromised by a negative equity balance of -$5.3M and a critical liquidity shortage, with cash reserves dwindling to just $3.1M. Investors should remain cautious as the firm's reliance on non-cash stock-based compensation, which reached $634M in 2026Q2, obscures the underlying operational losses and heightens the risk of further dilutive capital raises."
Verdict Logic
Negative: The company's cash runway is critically depleted with only $3.1M in cash remaining against a history of consistent quarterly free cash flow outflows exceeding $4M.
TRAW Growth Metrics
Traws Pharma, Inc. (TRAW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-13.17%
5 Years64.59%
3 Years131.12%
TTM606.33%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM76.36%
Return on Capital
10 Years-304.96%
5 Years-167.81%
3 Years-244.93%
Last Year-277.13%
TRAW Recent Earnings
Traws Pharma, Inc. (TRAW) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (20%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.53+42.4%
$0.92
Rev
—
$3M
Q2 2026
Apr 15, 2026Metric
Actual
Est
EPS
$0.71+42.0%
$1.22
Rev
—
$60,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.11+98.7%
$8.75
Rev
$3M+4455.0%
$60,000
Q2 2025
May 15, 2025Metric
Actual
Est
EPS
$2.09+126.0%
$8.04
Rev
$57,000-5.0%
$60,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.53vs $0.92+42.4% | —vs $3M |
| Q2 2026 | Apr 15, 2026 | $0.71vs $1.22+42.0% | —vs $60,000 |
| Q3 2025 | Aug 14, 2025 | $0.11vs $8.75+98.7% | $3Mvs $60,000+4455.0% |
| Q2 2025 | May 15, 2025 | $2.09vs $8.04+126.0% | $57,000vs $60,000-5.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Traws Pharma, Inc. (TRAW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.83 | $7.56M | 1.01 | 1134.51% | 328.67% | — | — | |
| $491.34 | $124.98B | 32.07 | 9.57% | 35.4% | 23.93% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $127.88 | $158.77B | 18.86 | 2.39% | 30.99% | 42.33% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $4.49 | $359.32M | -2.31 | — | — | -57.01% | — |
Compare TRAW vs Peers
Traws Pharma, Inc. (TRAW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TRAW SEC Filings & Documents
Traws Pharma, Inc. (TRAW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TRAW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TRAW Frequently Asked Questions
Traws Pharma, Inc. (TRAW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Traws Pharma, Inc.'s revenue?
Traws Pharma, Inc. (TRAW) reported $2.8M in revenue for fiscal year 2025. This represents a 88% increase from $1.5M in 2011.
How fast is Traws Pharma, Inc. growing?
Traws Pharma, Inc. (TRAW) grew revenue by 1134.5% over the past year. This is strong growth.
Is TRAW profitable?
Traws Pharma, Inc. (TRAW) reported a net loss of $23.9M for fiscal year 2025.
Dividend & Returns
What is Traws Pharma, Inc.'s free cash flow?
Traws Pharma, Inc. (TRAW) had negative free cash flow of $2.59B in fiscal year 2025, likely due to heavy capital investments.